New hope for Tough-to-Treat lung cancer: Two-Drug attack aims to shrink tumors
NCT ID NCT07158489
Summary
This study is testing whether combining an older chemotherapy drug (gemcitabine) with a newer two-target drug (ivonescimab) can help control advanced non-small cell lung cancer that has gotten worse despite standard treatment. It will involve about 47 adults whose cancer has progressed after chemo-immunotherapy. The main goal is to see if this combination can shrink tumors and for how long.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Fribourgeois - Hôpital Cantonal
Fribourg, Switzerland
-
Hôpitaux Universitaires de Genève
Geneva, 1211, Switzerland
-
IOSI Ospedale Regionale di Bellinzona e Valli
Bellinzona, 6500, Switzerland
-
Kantonsspital Baden
Baden, 5404, Switzerland
-
Kantonsspital Graubuenden
Chur, CH-7000, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
Universitätsspital Basel
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.